Table 3 Effect of methods on the percent of outcomes classified as new infections (n = 139).
Explanatory Variable | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
OR* (95% CI) | p-value | OR* (95% CI) | p-value | |
Number of markers | ||||
≥3 markers vs. 1–2 markers | 1· 09 (0.56–2· 13) | 0.80 | 1· 28 (0.45–3· 65) | 0.64 |
Classification of mixed results† | ||||
not always recrudescence vs. always recrudescence | 1· 92 (0.91–4· 03) | 0.09 | 3· 31 (1· 22–9· 01) | 0.02 |
Treatment group | ||||
artemisinin combination therapy vs. monotherapy | 8· 20 (3· 52–19· 11) | < 0.0001 | 8· 56 (3· 34–21· 94) | < 0.0001 |
non-artemisinin combination therapy vs. monotherapy | 2· 72 (1· 03–7· 16) | 0.04 | 2· 30 (0.82–6· 47) | 0.12 |
Geographic region | ||||
Africa vs. rest of the world | 0.87 (0.44–1· 71) | 0.68 | 3· 30 (1· 01–10.84) | 0.05 |
Maximum duration of follow-up | ||||
> 28 days vs. ≤ 28 days | 2· 54 (1· 23–5· 24) | 0.01 | 4.10 (1· 28–13· 15) | 0.02 |